{"id":56661,"date":"2026-02-09T20:55:04","date_gmt":"2026-02-09T12:55:04","guid":{"rendered":"https:\/\/flcube.com\/?p=56661"},"modified":"2026-02-09T20:55:05","modified_gmt":"2026-02-09T12:55:05","slug":"innocare-pharmas-icp-538-becomes-first-vav1-molecular-glue-degrader-to-enter-china-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56661","title":{"rendered":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials"},"content":{"rendered":"\n<p><strong>InnoCare Pharma Limited<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a><\/strong>) announced that its <strong>self-developed VAV1-targeting molecular glue degrader, ICP-538<\/strong>, has received <strong>clinical trial approval<\/strong> from the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>NMPA<\/strong>. The oral, highly potent degrader targets <strong>refractory autoimmune diseases<\/strong> including <strong>inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS)<\/strong>, marking a <strong>first-in-class entry<\/strong> into China\u2019s autoimmune pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>InnoCare Pharma (SHA: 688428, HKG: 9969)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>ICP-538 \u2013 VAV1-targeting molecular glue degrader<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Phase I clinical trial authorization<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Second VAV1 degrader worldwide to enter trials; <strong>first in China<\/strong><\/td><\/tr><tr><td><strong>Current Market<\/strong><\/td><td>No approved VAV1-targeted drugs globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-mechanism-of-action\">Technology Platform &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> <strong>Molecular glue degrader<\/strong> \u2013 Next\u2011generation protein degradation technology<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>VAV1 (Vav guanine nucleotide exchange factor 1)<\/strong> \u2013 Critical signaling node downstream of <strong>T-cell and B-cell receptors<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Forms <strong>ternary complex<\/strong> between <strong>CRBN E3 ubiquitin ligase<\/strong> and <strong>VAV1 protein<\/strong><\/li>\n\n\n\n<li>Induces <strong>rapid, potent, dose-dependent VAV1 degradation<\/strong> via proteasome pathway<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delivery:<\/strong> <strong>Oral administration<\/strong> \u2013 Potential convenience advantage over injectable biologics<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Highly specific for VAV1 vs. other VAV family members<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-indications-amp-autoimmune-focus\">Target Indications &amp; Autoimmune Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Disease<\/th><th>Unmet Need<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Inflammatory Bowel Disease (IBD)<\/strong><\/td><td>Limited oral options; biologic fatigue common<\/td><td>T\/B-cell modulation via VAV1 degradation<\/td><\/tr><tr><td><strong>Systemic Lupus Erythematosus (SLE)<\/strong><\/td><td>High disease burden; steroid dependence<\/td><td>Potential for disease-modifying therapy<\/td><\/tr><tr><td><strong>Multiple Sclerosis (MS)<\/strong><\/td><td>Progressive forms underserved<\/td><td>Neuroinflammation targeting through immune cell modulation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-strategic-positioning\">Competitive Landscape &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> As the <strong>second VAV1 degrader globally<\/strong> and <strong>first in China<\/strong>, ICP-538 secures <strong>regulatory and clinical data leadership<\/strong> in the world\u2019s second-largest pharmaceutical market.<\/li>\n\n\n\n<li><strong>Molecular Glue Differentiation:<\/strong> Unlike traditional kinase inhibitors or biologics, <strong>protein degraders<\/strong> offer <strong>catalytic mechanism<\/strong> (sub\u2011stoichiometric target elimination) and potential for <strong>improved efficacy in resistant populations<\/strong>.<\/li>\n\n\n\n<li><strong>InnoCare Platform Validation:<\/strong> ICP-538 advances InnoCare\u2019s <strong>protein degradation pipeline<\/strong> beyond oncology (BTK inhibitor orelabrutinib) into <strong>immunology<\/strong>, demonstrating platform versatility and expanding addressable market.<\/li>\n\n\n\n<li><strong>Autoimmune Market Scale:<\/strong> China\u2019s autoimmune disease therapeutics market is projected to exceed <strong>$15 billion by 2030<\/strong>, with significant unmet need in IBD and SLE where oral small molecules are limited.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Anticipated Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Phase I clinical trial initiation (CDE approved)<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>Single ascending dose and multiple ascending dose studies<\/td><td>2026<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Proof-of-concept in IBD, SLE, or MS patient populations<\/td><td>2027<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>Potential US\/EU IND filing based on China Phase I data<\/td><td>2026\u20112027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ICP-538 clinical development in autoimmune diseases, VAV1 target validation, and InnoCare Pharma\u2019s protein degradation platform expansion. Actual results may differ due to early\u2011stage clinical risks, competitive dynamics in the molecular glue space, and regulatory requirements for novel degrader mechanisms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,327,70],"class_list":["post-56661","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-innocare-pharma","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56661\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56661\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T12:55:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T12:55:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials\",\"datePublished\":\"2026-02-09T12:55:04+00:00\",\"dateModified\":\"2026-02-09T12:55:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"InnoCare Pharma\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56661#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56661\",\"name\":\"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T12:55:04+00:00\",\"dateModified\":\"2026-02-09T12:55:05+00:00\",\"description\":\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56661\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56661#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56661","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials","og_description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.","og_url":"https:\/\/flcube.com\/?p=56661","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T12:55:04+00:00","article_modified_time":"2026-02-09T12:55:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56661#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56661"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials","datePublished":"2026-02-09T12:55:04+00:00","dateModified":"2026-02-09T12:55:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56661"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","InnoCare Pharma","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56661#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56661","url":"https:\/\/flcube.com\/?p=56661","name":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T12:55:04+00:00","dateModified":"2026-02-09T12:55:05+00:00","description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader, ICP-538, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The oral, highly potent degrader targets refractory autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), marking a first-in-class entry into China\u2019s autoimmune pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56661#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56661"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56661#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma\u2019s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56661"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56661\/revisions"}],"predecessor-version":[{"id":56665,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56661\/revisions\/56665"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}